Frequency of the anti-glutamic acid decarboxylase immunological marker in patients with diabetes duration longer than three years in southern Brazil

被引:2
|
作者
Moreira, Marina Carolina [1 ]
Lara, Gustavo Mueller [2 ]
Linden, Rafael [3 ,4 ]
Feksa, Luciane Rosa [3 ,4 ]
Tavares, Rejane Giacomelli [3 ,4 ]
de Matos Almeida, Sabrina Esteves [3 ,4 ]
Berlese, Daiane Bolzan [4 ]
机构
[1] Univ Feevale, Novo Hamburgo, RS, Brazil
[2] Univ Feevale, Immunol Lab Course Undergrad Biomed, BR-93534490 Sao Jorge, RS, Brazil
[3] Univ Feevale, Inst Hlth Sci, BR-93534490 Sao Jorge, RS, Brazil
[4] Univ Feevale, Bioanal Res Grp, BR-93534490 Sao Jorge, RS, Brazil
来源
SAO PAULO MEDICAL JOURNAL | 2011年 / 129卷 / 03期
关键词
Antibodies; Diabetes mellitus; type; 1; Autoimmunity; Chronic disease; Incidence; MELLITUS; AUTOANTIBODIES;
D O I
10.1590/S1516-31802011000300002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
CONTEXT AND OBJECTIVE: The anti-GAD (glutamic acid decarboxylase) antibody is considered to be an important marker for type 1 diabetes mellitus (DM1), with frequency that varies depending on the population studied and the duration of the disease. Therefore, the aim of this study was to determine the frequency of this autoantibody in a group of patients in southern Brazil with DM1 that had been diagnosed more than three years previously. DESIGN AND SETTING: Analytical cross-sectional study with a control group conducted at the Biomedicine Laboratory of Universidade Feevale. METHODS: This study was conducted between June 2007 and December 2008, and 109 individuals were enrolled during this period. Fifty-eight were DM1 patients and 51 were individuals free from DM1 and without any history of diabetes, who constituted the control group. RESULTS: In the DM1 group, the mean age was 27 +/- 1.7 years and 50% were men. The mean fasting blood glucose in the DM1 group was 208 +/- 15 mg/dl and mean HbA1c (glycosylated hemoglobin) was 8.7 +/- 0.25%. In the control group, the mean fasting blood glucose and HbA1c were 82 mg/dl and 5.0% respectively. Thirty-seven individuals with DM1 (63.8%) were positive for anti-GAD, and this proportion was significantly larger than in the control group. CONCLUSIONS: These results show the high prevalence of anti-GAD in the population of diabetic patients in southern Brazil, thus indicating that the antibody was still present a long time after the disease had been diagnosed.
引用
收藏
页码:130 / 133
页数:4
相关论文
共 19 条
  • [1] Relationship between the prevalence of anti-glutamic acid decarboxylase autoantibodies and duration of type 1 diabetes mellitus in Brazilian patients
    Rodacki, M
    Zajdenverg, L
    Albernaz, MS
    Bencke-Gonçalves, MR
    Milech, A
    Oliveira, JEP
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2004, 37 (11) : 1645 - 1650
  • [2] A Case of Fulminant Type 1 Diabetes with Transient Production of Anti-Glutamic Acid Decarboxylase Antibody
    Harada, Naka
    Nakayama, Hitomi
    Nomura, Masatoshi
    AMERICAN JOURNAL OF CASE REPORTS, 2024, 25
  • [3] Prevalence and Clinical Characteristics of Recently Diagnosed Type 2 Diabetes Patients with Positive Anti-Glutamic Acid Decarboxylase Antibody
    Hwangbo, Yul
    Kim, Jin Taek
    Kim, Eun Ky
    Khang, Ah Reum
    Oh, Tae Jung
    Jang, Hak Chul
    Park, Kyong Soo
    Kim, Seong Yeon
    Lee, Hong Kyu
    Cho, Young Min
    DIABETES & METABOLISM JOURNAL, 2012, 36 (02) : 136 - 143
  • [4] Are anti-glutamic acid decarboxylase 65-kDa isoform antibodies related to diabetes or brain tumor?
    Maimaiti, Buajieerguli
    Mijiti, Salamaitiguli
    Sun, Huaiyu
    Xie, Yinyin
    Jiang, Ting
    Meng, Qian
    Meng, Hongmei
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2022, 27 (01)
  • [5] Experience with imnnunotherapy in 3 patients with cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies
    Rouco, I.
    Hurtado, P.
    Castano, L.
    Zarranz, J. J.
    NEUROLOGIA, 2015, 30 (04): : 247 - 249
  • [6] Clinical characteristics of anti-glutamic acid decarboxylase antibody-positive fulminant type 1 diabetes
    Saito, Daigo
    Oikawa, Yoichi
    Mizutani, Gen
    Inoue, Kazuyuki
    Hatano, Masako
    Inoue, Ikuo
    Noda, Mitsuhiko
    Shimada, Akira
    ENDOCRINE JOURNAL, 2019, 66 (04) : 329 - 336
  • [7] Are anti-glutamic acid decarboxylase 65-kDa isoform antibodies related to diabetes or brain tumor?
    Buajieerguli Maimaiti
    Salamaitiguli Mijiti
    Huaiyu Sun
    Yinyin Xie
    Ting Jiang
    Qian Meng
    Hongmei Meng
    European Journal of Medical Research, 27
  • [8] Circulating anti-glutamic acid decarboxylase-65 antibody titers are positively associated with the capacity of insulin secretion in acute-onset type 1 diabetes with short duration in a Japanese population
    Yamamura, So
    Fukui, Tomoyasu
    Mori, Yusaku
    Hayashi, Toshiyuki
    Yamamoto, Takeshi
    Ohara, Makoto
    Fukase, Ayako
    Sasamori, Hiroto
    Kobayashi, Tetsuro
    Hirano, Tsutomu
    JOURNAL OF DIABETES INVESTIGATION, 2019, 10 (06) : 1480 - 1489
  • [9] Serum titres of anti-glutamic acid decarboxylase-65 and anti-IA-2 autoantibodies are associated with different immunoregulatory milieu in newly diagnosed type 1 diabetes patients
    Andrade Lima Gabbay, M.
    Sato, M. N.
    Duarte, A. J. S.
    Dib, S. A.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2012, 168 (01) : 60 - 67
  • [10] A patient with type 1 diabetes mellitus and cerebellar ataxia associated with high titer of circulating anti-glutamic acid decarboxylase antibodies
    Iwasaki, H
    Sato, R
    Shichiri, M
    Hirata, Y
    ENDOCRINE JOURNAL, 2001, 48 (02) : 261 - 268